Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 375 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Five Questions with…Jennifer. March 24, 2022 FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical... January 25, 2024 What to Know When Searching for Cancer Information Online: An Expert... December 7, 2021 How keeping active during cancer treatment has helped Mary and Keith September 26, 2022 Load more HOT NEWS Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... Severe mental illness linked to low attendance at cancer screening Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over...
